7/8/22, 1 :24 PM
`
`Bausch + Lomb Corporation Is Now Trading Under BLCO Ticker!
`
`(/)
`
`Bausch + Lomb Corporation Is Now Trading Under BLCO Ticker!
`MAY 6, 2022
`
`As you may have seen, Bausch+ Lomb Corporation began trading today on the New York Stock Exchange and Toronto Stock
`Exchange under the ticker BLCO.1
`
`This is a tremendous milestone for our company, and gets us closer to our ambitious goal of providing as many patients as
`possible around the globe with a lifetime of healthy vision. What first began in 1853 as a small optical goods shop in Rochester,
`New York, is now a fully integrated eye care company - inclusive of Vision Care, Consumer Health Care, Surgical and
`Ophthalmic Pharmaceuticals - that is well positioned to support consumers, eye care professionals and patients across t he full
`spectrum of eye health.
`
`For nearly two centuries, Bausch+ Lomb has remained focused on advancing eye health for people all over the world,
`pioneering hundreds of innovations. While eye care has evolved, our relentless work to bring innovations to help patients
`improve their quality of sight has only grown stronger. Today, that legacy of innovation continues through our comprehensive
`portfolio of more than 400 products, which includes contact lenses, lens and eye care products, ophthalmic pharmaceuticals,
`over-the-counter products and ophthalmic surgical devices and instruments.
`
`Additionally, through our inherent culture of resourcefulness and continued investment in future innovations, our research
`and development, quality, manufacturing and commercial teams work hand-in-hand each day to fulfil the unmet needs in the
`industry.
`
`We have a substantial pipeline in various stages of pre-clinical and clinical development, including new over-the-counter eye
`care products, contact lenses, innovative soft\Nare and prescription medications for myopia management, next-generation
`cataract and LASIK surgical equipment, premium intraocular lenses, investigational treatments for dry eye and preservative(cid:173)
`free formulations of a range of eye drops.
`
`In order to continue to deliver on our mission of helping people see better to live better through business practices that
`strengthen communities and enrich lives, we have put in place a strong leadershiP- team (/about-bausch-lomb/management(cid:173)
`.tfa!IIL). that will help lead us into the future.
`
`Together with this team and our approximately 12,000 employees around the globe, we remain steadfast in our commitment
`to protect and enhance the gift of sight for millions of people around the world - from the moment of birth through every
`phase of life.
`
`Best regards,
`
`-1{2
`
`Joseph C. Papa
`
`Chairman and Chief Executive Officer
`
`Bausch + Lomb
`
`1 The common shares have been approved for listing on the New York Stock Exchange ("NYSE") and conditionally approved for listing on the
`Toronto Stock Exchange ("TSX"). The common shares begin trading on the NYSE and on an "if, as and when issued basis" on the TSX on May 6,
`2022; and the /PO is expected to close on May 10, 2022, subject to customary closing conditions.
`
`https://www.bausch.com/news/messages-from-ceo/article/ 1/
`
`1/2
`
`Eye Therapies Exhibit 2083, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`7/8/22, 1 :24 PM
`
`Bausch+ Lomb Corporation Is Now Trading Under BLCO Ticker!
`
`BAUSCH + LOMB</)
`See bette r. Live bette r.
`
`I) (https://www.facebook.com/BauschandLomb/) @) (https://www.instagram.com/bauschlomb/) W
`(https://twitter.com/Bauschlomb) m, (https://www.linkedin.com/company/bausch-&-lomb)
`
`Contact us (/about-bausch-lomb/contact·us/)
`
`Procurement (/procurement/)
`
`E:mall preferences (http://cloud.marketlng.bausch.com/Prlvacy·Page·Unsubscrlbe)
`
`Privacy pollcy (!privacy/)
`
`Legal notice Uterms/)
`
`Site map (/site-map/)
`
`e 2022 Bau.sch & Lomb lncorporatgd or its affiliates. MTB.0nS.USA.21
`
`All Information and materials on this site p@rtain to the U.S. only, unless otherwiw indicated.
`
`CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION {btto-//'ilottrl marketing bausch com/ralitornla·gcjyafy-9gtouv
`
`https://www.bausch.com/news/messages-from-ceo/article/1/
`
`212
`
`Eye Therapies Exhibit 2083, 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`